Search | Clinical Trials Finder

Conditions: Asthma
Interventions: CHF 1531 pMDI, Formoterol Inhalation Solution, Placebo pMDI; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Lutherville, Maryland + 7 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Revefenacin, Placebo, Formoterol; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 193
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 155 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 19
States / cities: Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more

Conditions: Asthma
Interventions: Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Budesonide/formoterol pMDI, Formoterol Turbuhaler; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 131
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more

Conditions: Asthma
Interventions: Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF; Drug
Lead sponsor: Novartis; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more

Conditions: COPD
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 52
States / cities: Jasper, Alabama • Phoenix, Arizona • Buena Park, California + 47 more

Conditions: COPD
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 44
States / cities: Jasper, Alabama • Phoenix, Arizona • Tuscon, Arizona + 40 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina

Conditions: COPD
Interventions: Arformoterol (Brovana), Placebo; Drug
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 40 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Asthma
Interventions: GP MDI, BFF MDI, Placebo MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Bakersfield, California • Lancaster, California • Long Beach, California + 12 more

Conditions: Asthma
Interventions: Formatris 24µg, Formatris 12µg, Foradil P 24µg, Foradil P 12µg; Drug
Lead sponsor: MEDA Pharma GmbH & Co. KG; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin

Conditions: Asthma
Interventions: FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 19
States / cities: Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 73
States / cities: Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more

Conditions: Asthma
Interventions: indacaterol maleate; Drug
Lead sponsor: Novartis; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: COPD
Interventions: PT010 Dose 1, PT010 Dose 2, Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 44
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 921 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 179
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler; Drug
Lead sponsor: William Stringer, md; Other
Eligibility: 40 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Torrance, California

Search by objective public record fields.

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD